This invention relates to apparatus and method for implanting a conduit to allow communication of fluids from one portion of a patient's body to another; and, more particularly, to a blood flow conduit to allow communication from a heart chamber to a vessel or vice versa, and/or vessel to vessel. Even more particularly, the invention relates to a left ventricular conduit and related conduit configurations having a blood vessel graft incorporated therein for controlling the flow of blood through the conduit to achieve bypass of an occluded or stenosed coronary artery.
Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque which, at the very least, can reduce blood and oxygen flow to the heart muscle (myocardium), and may impair the efficiency of the heart's pumping action, and can lead to heart attack (myocardial infarction) and death. In some cases, these coronary arteries can be unblocked through noninvasive techniques such as balloon angioplasty. In more difficult cases, a surgical bypass of the blocked vessel is necessary.
In a coronary bypass operation, one or more venous segments are inserted between the aorta and the coronary artery, or, alternatively, the distal end of an internal mammary artery is anastomosed to the coronary artery at a site distal to the stenosis or occlusion. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.
Such coronary artery bypass graft (CABG) surgery, however, is a very intrusive procedure which is expensive, time-consuming, and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a heart-lung bypass pump so that the heart can be operated on while not beating. A saphenous vein graft is harvested from the patient's leg, another highly invasive procedure, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged. Furthermore, many patients are poor surgical candidates due to other concomitant illnesses.
As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type or location of the blockage or stenosis, or due to the risk of emboli.
Thus, there is a need for an improved coronary bypass system which is less traumatic to the patient.
The present invention addresses the need in the previous technology by providing a coronary bypass system which avoids a sternotomy and other intrusive aspects associated with coronary bypass surgery. It also frees the surgeon from having to perform multiple anastomoses, as is necessary in the current process.
The present device provides a conduit for diverting blood directly from a heart chamber, such as the left ventricle of the heart, to the coronary artery distal to the blockage or stenosis, thereby bypassing the blocked portion of the vessel. The conduit comprises a tube adapted to be positioned in the heart wall and having a section of blood vessel attached to the interior of the conduit, to provide a passage for blood flow which is similar to the body's own blood vessels.
The conduit device is delivered through the coronary artery to a position distal the blockage or stenosis. At that position, the coronary artery and the wall of the left ventricle, including the myocardium, are pierced to provide an opening or channel completely through from the coronary artery to the left ventricle of the heart. The conduit is then positioned in the opening to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage or stenosis.
The conduit is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. Prior to implantation of the conduit, a section of vein or other blood vessel is obtained from the patient, from another human donor, or from a nonhuman animal. The vein or other blood vessel is sized so as to fit within the interior of the conduit. The hollow lumen of the conduit with the blood vessel graft inserted therein provides a passage for the flow of blood.
If desired, the section of blood vessel inserted into the conduit may include one or more naturally occurring one-way valves. The valve prevents the backflow of blood from the myocardium into the left ventricle. For example, a section of vein having a valve therein can be used. Alternatively, the pulmonic valve or aortic valve obtained from a nonhuman animal, such as a fetal pig or piglet, can be used to provide a one-way passage for the flow of blood through the conduit.
As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. Oxygenated blood that has returned from the lungs to the heart then flows from the heart to the aorta. Some blood in the aorta flows into the coronary arteries, and the remainder of blood in the aorta flows on to the rest of the body. The coronary arteries are the primary blood supply to the heart muscle and are thus critical to life. In some individuals, atherosclerotic plaque, aggregated platelets, and/or thrombi build up within the coronary artery, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death. The presence of coronary vasospasm, also known as “variant angina” or “Prinzmetal's angina,” compounds this problem in many patients.
As used herein, the term “heart chamber” primarily refers to the interior, or lumenal, aspect of the left or right ventricle or the left or right atrium. The term “conduit,” “stent,” and “tube” herein refer to physical structures, preferably primarily artificial, that can be positioned between two or more chambers or vessels, to allow blood flow from one chamber or vessel to another. A “shunt” is any natural or artificial passage between natural channels, such as heart chambers or blood vessels. The conduit in the preferred arrangement can be made of a variety of materials, including various metals, such as nitinol, or plastics.
As used herein, the term “heart wall” comprises any one or more of the following portions or layers of the mammalian heart: the epicardium, myocardium, endocardium, pericardium, interatrial septum, and interventricular septum.
The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.
In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other nonmyocardial and even noncardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.
The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the obstructions that are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.
The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.
The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods are disclosed. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.
In order to restore the flow of oxygenated blood through the coronary artery, the preferred arrangement provides for the shunting of blood directly from the heart to a site in the coronary artery which is distal the blockage or stenosis.
Although the specification herein will describe the conduit primarily with reference to the left ventricle, the preferred arrangement can be used with any of the four heart chambers, and with any coronary artery, including the left main coronary artery, the right coronary artery, the left anterior descending artery, the left circumflex artery, the posterior descending artery, the obtuse marginal branch or a diagonal branch.
A tunnel or opening is formed through the wall of the coronary artery and the myocardium and into the left ventricle of the heart which lies beneath, or deep to, the coronary artery. A conduit is positioned in the opening to keep it open.
The conduit may be introduced into the myocardium in a variety of ways, including by a catheter threaded through the femoral artery into the aorta and thence into the left ventricle and, if necessary, the left atrium; or by a catheter threaded through the femoral vein into the inferior vena cava and thence into the right atrium and right ventricle. Alternatively, the conduit may be introduced through a surgical incision in chest wall (thoracotomy) or sternum (sternotomy).
Further details regarding conduits and conduit delivery systems are described in copending patent applications entitled, DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,048, filed Aug. 4, 1999, VALVE DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/368,393, filed Aug. 4, 1999, LEFT VENTRICULAR CONDUITS TO CORONARY ARTERIES AND METHODS FOR CORONARY BYPASS, U.S. Application Ser. No. 09/534,038, filed Mar. 24, 2000, and BLOOD FLOW CONDUIT DELIVERY SYSTEM AND METHOD OF USE, U.S. application Ser. No. 09/368,644, filed Aug. 4, 1999, and U.S. Pat. Nos. 6,261,304, 5,429,144 and 5,662,124, the disclosures of which are all hereby incorporated by reference in their entirety.
The opening through the heart wall (including endocardium, myocardium, and epicardium) and coronary artery can be formed in a variety of ways, including by knife or scalpel, electrocautery, cryoablation, radiofrequency ablation, ultrasonic ablation, and the like. Other methods will be apparent to those of ordinary skill in the art.
The conduit is provided with a section of vein or other blood vessel positioned within its interior lumen. The section of vein or other blood vessel is obtained from the patient, from a donor, or from an animal. Prior to implantation of the conduit, a segment of blood vessel sized to fit with the lumen of the conduit is inserted into the conduit. The conduit with the graft therein provides a passage for the flow of blood which is similar to the natural human blood vessels. The segment of vein or other blood vessel harvested to fit within the conduit may include one or more of the valves which naturally occur in the human body. These valves act to prevent the backflow of blood. In the conduit, these naturally occurring venous valves prevent the blood from flowing back into the left ventricle of the heart from the coronary artery. The segment of vein is preferably inserted into the conduit prior to the conduit's deployment into the human body by any of various surgical or catheter-guided techniques known to those of skill in the art.
Referring now to
As shown in
As noted above, the section of vein 10 or other blood vessel harvested preferably contains one or more valves 14, which occur naturally in the veins. The section of vein 10 may also not have a valve. The vein section 10 is sized so as to be the same length as the conduit 12. The vein section 10 is placed within the interior lumen of the conduit 12 and attached to the inside of the conduit 12 by suturing or other attachment methods. The natural vein graft 10 is biocompatible and therefore reduces problems associated with rejection of the conduit 12 and clotting around or in the conduit 12. In addition, the vein 10 provides a natural valve system 14 that is already used throughout the human body to prevent the backflow of blood. In the case of a xenograft, treatment of the graft with chemicals, such as glutaraldehyde, may be undertaken to remove living cells, including antigenic materials, from the connective tissue framework of the graft so as to reduce thrombogenicity and antigenicity.
Referring now to
The conduit 12 may include attachment mechanisms not limited to hooks, barbs, large collars, and/or other methods to ensure that a seal is created between the coronary artery CA and the wall of the heart wall MYO, to prevent hemorrhaging and to prevent the threat of or actual conduit migration. When positioning and securing of the conduit 12 is completed, the remaining catheter assembly is removed, leaving the conduit 12 with the vein graft therein, in place in the body
The present vascular conduit having a blood vessel graft incorporated therein provides significant improvements in the present treatment of blockages or stenoses in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way by the foregoing.
This is a continuation of U.S. application Ser. No. 09/369,061, filed Aug. 4, 1999 now U.S. Pat. No. 6,254,564, which claims the benefits of U.S. Provisional Application No. 60/099,719, filed Sep. 10, 1998, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4118806 | Porier et al. | Oct 1978 | A |
4441215 | Kaster | Apr 1984 | A |
4546499 | Possis et al. | Oct 1985 | A |
4562597 | Possis et al. | Jan 1986 | A |
4733665 | Palmaz | Mar 1988 | A |
4769029 | Patel | Sep 1988 | A |
4953553 | Tremulis | Sep 1990 | A |
5147388 | Yamazaki | Sep 1992 | A |
5193546 | Shaknovich | Mar 1993 | A |
5258008 | Wilk | Nov 1993 | A |
5275580 | Yamazaki | Jan 1994 | A |
5287861 | Wilk | Feb 1994 | A |
5330486 | Wilk | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5389096 | Aita et al. | Feb 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5470320 | Tifenbrun et al. | Nov 1995 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5554119 | Harrison et al. | Sep 1996 | A |
5571167 | Maginot | Nov 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5593434 | Williams | Jan 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5655548 | Nelson et al. | Aug 1997 | A |
5662124 | Wilk | Sep 1997 | A |
5733267 | Del Toro | Mar 1998 | A |
5755682 | Knudson | May 1998 | A |
5758663 | Wilk et al. | Jun 1998 | A |
5797946 | Chin | Aug 1998 | A |
5807384 | Mueller | Sep 1998 | A |
5810836 | Hussein et al. | Sep 1998 | A |
5824038 | Wall | Oct 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5830222 | Makower | Nov 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5865723 | Love | Feb 1999 | A |
5876373 | Giba et al. | Mar 1999 | A |
5878751 | Hussein et al. | Mar 1999 | A |
5885259 | Berg | Mar 1999 | A |
5908028 | Wilk | Jun 1999 | A |
5908029 | Knudson et al. | Jun 1999 | A |
5922022 | Nash et al. | Jul 1999 | A |
5925012 | Murphy-Chutorian et al. | Jul 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5935119 | Guy et al. | Aug 1999 | A |
5935161 | Robinson et al. | Aug 1999 | A |
5938632 | Ellis | Aug 1999 | A |
5944019 | Knudson et al. | Aug 1999 | A |
5971993 | Hussein et al. | Oct 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
5976178 | Goldstein et al. | Nov 1999 | A |
5976192 | McIntyre et al. | Nov 1999 | A |
5976650 | Campbell et al. | Nov 1999 | A |
5979455 | Maginot | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5980548 | Evans et al. | Nov 1999 | A |
5984956 | Tweden et al. | Nov 1999 | A |
5989276 | Houser et al. | Nov 1999 | A |
5989287 | Yang et al. | Nov 1999 | A |
5993481 | Marcade et al. | Nov 1999 | A |
5997525 | March et al. | Dec 1999 | A |
5997563 | Kretzers | Dec 1999 | A |
5997573 | Quijano et al. | Dec 1999 | A |
5999678 | Murphy-Chutorian et al. | Dec 1999 | A |
6001123 | Lau | Dec 1999 | A |
6004261 | Sinofsky et al. | Dec 1999 | A |
6004347 | McNamara et al. | Dec 1999 | A |
6004348 | Banas et al. | Dec 1999 | A |
6007543 | Ellis et al. | Dec 1999 | A |
6010449 | Selmon et al. | Jan 2000 | A |
6026814 | LaFontaine et al. | Feb 2000 | A |
6029672 | Vanney et al. | Feb 2000 | A |
6033582 | Lee et al. | Mar 2000 | A |
6035856 | LaFontaine et al. | Mar 2000 | A |
6036677 | Javier, Jr. et al. | Mar 2000 | A |
6036697 | DiCaprio | Mar 2000 | A |
6042581 | Ryan et al. | Mar 2000 | A |
6045565 | Ellis et al. | Apr 2000 | A |
6053924 | Hussein | Apr 2000 | A |
6053942 | Eno et al. | Apr 2000 | A |
6056743 | Ellis et al. | May 2000 | A |
6067988 | Mueller | May 2000 | A |
6068638 | Makower | May 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6076529 | Vanney et al. | Jun 2000 | A |
6080163 | Hussein et al. | Jun 2000 | A |
6080170 | Nash et al. | Jun 2000 | A |
6092526 | LaFontaine et al. | Jul 2000 | A |
6093166 | Knudson et al. | Jul 2000 | A |
6093177 | Javier, Jr. et al. | Jul 2000 | A |
6093185 | Ellis et al. | Jul 2000 | A |
6102941 | Tweden et al. | Aug 2000 | A |
6113630 | Vanney et al. | Sep 2000 | A |
6113823 | Eno | Sep 2000 | A |
6120520 | Saadat et al. | Sep 2000 | A |
6123682 | Knudson et al. | Sep 2000 | A |
6126649 | VanTassel et al. | Oct 2000 | A |
6126654 | Giba et al. | Oct 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6132451 | Payne et al. | Oct 2000 | A |
6139541 | Vanney et al. | Oct 2000 | A |
6155264 | Ressemann et al. | Dec 2000 | A |
6156031 | Aita et al. | Dec 2000 | A |
6157852 | Selmon et al. | Dec 2000 | A |
6159225 | Makower | Dec 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6165185 | Shennib et al. | Dec 2000 | A |
6165188 | Saadat et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171251 | Mueller et al. | Jan 2001 | B1 |
6182668 | Tweden et al. | Feb 2001 | B1 |
6186972 | Nelson et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6193726 | Vanney | Feb 2001 | B1 |
6196230 | Hall et al. | Mar 2001 | B1 |
6197050 | Eno et al. | Mar 2001 | B1 |
6197296 | Davies et al. | Mar 2001 | B1 |
6197324 | Crittenden | Mar 2001 | B1 |
6200311 | Danek et al. | Mar 2001 | B1 |
6203556 | Evans et al. | Mar 2001 | B1 |
6213126 | LaFontaine et al. | Apr 2001 | B1 |
6214041 | Tweden et al. | Apr 2001 | B1 |
6217527 | Selmon et al. | Apr 2001 | B1 |
6217549 | Selmon et al. | Apr 2001 | B1 |
6217575 | DeVore et al. | Apr 2001 | B1 |
6221049 | Selmon et al. | Apr 2001 | B1 |
6223752 | Vanney et al. | May 2001 | B1 |
6224584 | March et al. | May 2001 | B1 |
6231546 | Milo et al. | May 2001 | B1 |
6231551 | Barbut | May 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6235000 | Milo et al. | May 2001 | B1 |
6237607 | Vanney et al. | May 2001 | B1 |
6238406 | Ellis et al. | May 2001 | B1 |
6241667 | Vetter et al. | Jun 2001 | B1 |
6241741 | Duhaylongsod et al. | Jun 2001 | B1 |
6248112 | Gambale et al. | Jun 2001 | B1 |
6250305 | Tweden | Jun 2001 | B1 |
6251079 | Gambale et al. | Jun 2001 | B1 |
6251116 | Shennib et al. | Jun 2001 | B1 |
6251418 | Ahern et al. | Jun 2001 | B1 |
6253768 | Wilk | Jul 2001 | B1 |
6253769 | LaFontaine et al. | Jul 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6258052 | Milo | Jul 2001 | B1 |
6258119 | Hussein et al. | Jul 2001 | B1 |
6261304 | Hall et al. | Jul 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6285903 | Rosenthal et al. | Sep 2001 | B1 |
6287317 | Makower et al. | Sep 2001 | B1 |
6290709 | Ellis et al. | Sep 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6330884 | Kim | Dec 2001 | B1 |
6350248 | Knudson et al. | Feb 2002 | B1 |
6361519 | Knudson et al. | Mar 2002 | B1 |
6363938 | Saadat et al. | Apr 2002 | B1 |
6363939 | Wilk | Apr 2002 | B1 |
6375615 | Flaherty et al. | Apr 2002 | B1 |
6379319 | Garibotto et al. | Apr 2002 | B1 |
6387119 | Wolf et al. | May 2002 | B1 |
6390098 | LaFontaine et al. | May 2002 | B1 |
6395208 | Herweck et al. | May 2002 | B1 |
6402740 | Ellis et al. | Jun 2002 | B1 |
6406488 | Tweden et al. | Jun 2002 | B1 |
6406491 | Vanney | Jun 2002 | B1 |
6409697 | Eno et al. | Jun 2002 | B1 |
6409751 | Hall et al. | Jun 2002 | B1 |
6416490 | Ellis et al. | Jul 2002 | B1 |
6423089 | Gingras et al. | Jul 2002 | B1 |
6432119 | Saadat | Aug 2002 | B1 |
6432126 | Gambale et al. | Aug 2002 | B1 |
6432127 | Kim et al. | Aug 2002 | B1 |
6432132 | Cottone et al. | Aug 2002 | B1 |
6443158 | LaFontaine et al. | Sep 2002 | B1 |
6447522 | Gambale et al. | Sep 2002 | B1 |
6447539 | Nelson et al. | Sep 2002 | B1 |
6454760 | Vanney | Sep 2002 | B1 |
6454794 | Knudson et al. | Sep 2002 | B1 |
6458092 | Gambale et al. | Oct 2002 | B1 |
6458140 | Akin et al. | Oct 2002 | B1 |
6458323 | Boekstegers | Oct 2002 | B1 |
6464709 | Shennib et al. | Oct 2002 | B1 |
6475226 | Belef et al. | Nov 2002 | B1 |
6475244 | Herweck et al. | Nov 2002 | B1 |
6482220 | Mueller | Nov 2002 | B1 |
6491689 | Ellis et al. | Dec 2002 | B1 |
6491707 | Makower et al. | Dec 2002 | B1 |
6508825 | Selmon et al. | Jan 2003 | B1 |
6511458 | Milo et al. | Jan 2003 | B1 |
6514217 | Selmon et al. | Feb 2003 | B1 |
6514271 | Evans et al. | Feb 2003 | B1 |
6517558 | Gittings et al. | Feb 2003 | B1 |
6524323 | Nash et al. | Feb 2003 | B1 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6559132 | Holmer | May 2003 | B1 |
6561998 | Roth et al. | May 2003 | B1 |
6565528 | Mueller | May 2003 | B1 |
6565594 | Herweck et al. | May 2003 | B1 |
6569145 | Shmulewitz et al. | May 2003 | B1 |
6569147 | Evans et al. | May 2003 | B1 |
6610100 | Phelps et al. | Aug 2003 | B1 |
6641610 | Wolf et al. | Nov 2003 | B1 |
6651670 | Rapacki et al. | Nov 2003 | B1 |
6666863 | Wentzel et al. | Dec 2003 | B1 |
6669709 | Cohn et al. | Dec 2003 | B1 |
6685648 | Flaherty et al. | Feb 2004 | B1 |
6694983 | Wolf et al. | Feb 2004 | B1 |
20010000041 | Selmon et al. | Mar 2001 | A1 |
20010004683 | Gambale et al. | Jun 2001 | A1 |
20010004690 | Gambale et al. | Jun 2001 | A1 |
20010004699 | Gittings et al. | Jun 2001 | A1 |
20010008969 | Evans et al. | Jul 2001 | A1 |
20010012948 | Vanney | Aug 2001 | A1 |
20010014813 | Saadat et al. | Aug 2001 | A1 |
20010016700 | Eno et al. | Aug 2001 | A1 |
20010018596 | Selmon et al. | Aug 2001 | A1 |
20010020172 | Selmon et al. | Sep 2001 | A1 |
20010025643 | Foley | Oct 2001 | A1 |
20010027287 | Shmulewitz et al. | Oct 2001 | A1 |
20010029385 | Shennib et al. | Oct 2001 | A1 |
20010034547 | Hall et al. | Oct 2001 | A1 |
20010037117 | Gambale et al. | Nov 2001 | A1 |
20010037149 | Wilk | Nov 2001 | A1 |
20010039426 | Makower et al. | Nov 2001 | A1 |
20010039445 | Hall et al. | Nov 2001 | A1 |
20010041902 | Lepulu et al. | Nov 2001 | A1 |
20010044631 | Akin et al. | Nov 2001 | A1 |
20010047165 | Makower et al. | Nov 2001 | A1 |
20010049523 | DeVore et al. | Dec 2001 | A1 |
20010053932 | Phelps et al. | Dec 2001 | A1 |
20020002349 | Flaherty et al. | Jan 2002 | A1 |
20020004662 | Wilk | Jan 2002 | A1 |
20020004663 | Gittings et al. | Jan 2002 | A1 |
20020007138 | Wilk et al. | Jan 2002 | A1 |
20020029079 | Kim et al. | Mar 2002 | A1 |
20020032476 | Gambale et al. | Mar 2002 | A1 |
20020049486 | Knudson et al. | Apr 2002 | A1 |
20020058897 | Renati | Apr 2002 | A1 |
20020062146 | Makower et al. | May 2002 | A1 |
20020065478 | Knudson et al. | May 2002 | A1 |
20020072699 | Knudson et al. | Jun 2002 | A1 |
20020077566 | Laroya et al. | Jun 2002 | A1 |
20020077654 | Javier, Jr. et al. | Jun 2002 | A1 |
20020092535 | Wilk | Jul 2002 | A1 |
20020092536 | LaFontaine et al. | Jul 2002 | A1 |
20020095111 | Tweden et al. | Jul 2002 | A1 |
20020100484 | Hall et al. | Aug 2002 | A1 |
20020111627 | Kim et al. | Aug 2002 | A1 |
20020123698 | Garibotto et al. | Sep 2002 | A1 |
20020123786 | Gittings et al. | Sep 2002 | A1 |
20020138087 | Shennib et al. | Sep 2002 | A1 |
20020143285 | Eno et al. | Oct 2002 | A1 |
20020143289 | Ellis et al. | Oct 2002 | A1 |
20020144696 | Sharkaway et al. | Oct 2002 | A1 |
20020161383 | Akin et al. | Oct 2002 | A1 |
20020161424 | Rapacki et al. | Oct 2002 | A1 |
20020165479 | Wilk | Nov 2002 | A1 |
20020165606 | Wolf et al. | Nov 2002 | A1 |
20020179098 | Makower et al. | Dec 2002 | A1 |
20020183716 | Herweck et al. | Dec 2002 | A1 |
20020193782 | Ellis et al. | Dec 2002 | A1 |
20030018379 | Knudson et al. | Jan 2003 | A1 |
20030044315 | Boekstegers | Mar 2003 | A1 |
20030045828 | Wilk | Mar 2003 | A1 |
20030055371 | Wolf et al. | Mar 2003 | A1 |
20030073973 | Evans et al. | Apr 2003 | A1 |
20030078561 | Gambale et al. | Apr 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030105514 | Phelps et al. | Jun 2003 | A1 |
20030120195 | Milo et al. | Jun 2003 | A1 |
20030181938 | Roth et al. | Sep 2003 | A1 |
20030195458 | Phelps et al. | Oct 2003 | A1 |
20030216679 | Wolf et al. | Nov 2003 | A1 |
20030236542 | Makower | Dec 2003 | A1 |
20040015225 | Kim et al. | Jan 2004 | A1 |
20040019348 | Stevens et al. | Jan 2004 | A1 |
Number | Date | Country |
---|---|---|
0 732 088 | Sep 1996 | EP |
0 815 798 | Jul 1997 | EP |
0 829 239 | Aug 1997 | EP |
0 792 624 | Sep 1997 | EP |
0 797 957 | Oct 1997 | EP |
0 797 958 | Oct 1997 | EP |
0 799 604 | Oct 1997 | EP |
0 801 928 | Oct 1997 | EP |
0 836 834 | Oct 1997 | EP |
0 876 796 | May 1998 | EP |
0 853 921 | Jul 1998 | EP |
0 858 779 | Aug 1998 | EP |
0 876 803 | Nov 1998 | EP |
0 888 750 | Jan 1999 | EP |
0 895 752 | Feb 1999 | EP |
1 020 166 | Jul 2000 | EP |
1 027 870 | Aug 2000 | EP |
1 097 676 | May 2001 | EP |
1 166 721 | Jan 2002 | EP |
0 959 815 | Dec 2002 | EP |
2 316 322 | Feb 1998 | GB |
WO 9632972 | Oct 1996 | WO |
WO 9635469 | Nov 1996 | WO |
WO 9639962 | Dec 1996 | WO |
WO 9639964 | Dec 1996 | WO |
WO 9639965 | Dec 1996 | WO |
9713463 | Apr 1997 | WO |
9713471 | Apr 1997 | WO |
9727893 | Aug 1997 | WO |
9727897 | Aug 1997 | WO |
WO 9727898 | Aug 1997 | WO |
9732551 | Sep 1997 | WO |
WO 9743961 | Nov 1997 | WO |
WO 9803118 | Jan 1998 | WO |
9806356 | Feb 1998 | WO |
9808456 | Mar 1998 | WO |
9810714 | Mar 1998 | WO |
9816161 | Apr 1998 | WO |
WO 9824373 | Jun 1998 | WO |
WO 9825533 | Jun 1998 | WO |
WO 9838916 | Sep 1998 | WO |
WO 9838925 | Sep 1998 | WO |
WO 9838939 | Sep 1998 | WO |
WO 9838941 | Sep 1998 | WO |
WO 9839038 | Sep 1998 | WO |
9844869 | Oct 1998 | WO |
9846115 | Oct 1998 | WO |
9846119 | Oct 1998 | WO |
9849964 | Nov 1998 | WO |
9853759 | Dec 1998 | WO |
9855027 | Dec 1998 | WO |
WO 9857590 | Dec 1998 | WO |
9857591 | Dec 1998 | WO |
WO 9857592 | Dec 1998 | WO |
WO 9907296 | Feb 1999 | WO |
9908624 | Feb 1999 | WO |
9949793 | Mar 1999 | WO |
WO 9915220 | Apr 1999 | WO |
WO 9917671 | Apr 1999 | WO |
9917683 | Apr 1999 | WO |
9921490 | May 1999 | WO |
9921510 | May 1999 | WO |
WO 9922655 | May 1999 | WO |
9922656 | May 1999 | WO |
WO 9922658 | May 1999 | WO |
9925273 | May 1999 | WO |
WO 9927985 | Jun 1999 | WO |
WO 9935977 | Jul 1999 | WO |
WO 9935979 | Jul 1999 | WO |
WO 9935980 | Jul 1999 | WO |
9936000 | Jul 1999 | WO |
9936001 | Jul 1999 | WO |
9938459 | Aug 1999 | WO |
WO 9940853 | Aug 1999 | WO |
9940868 | Aug 1999 | WO |
WO 9940963 | Aug 1999 | WO |
WO 9944524 | Sep 1999 | WO |
9947071 | Sep 1999 | WO |
9948545 | Sep 1999 | WO |
WO 9948549 | Sep 1999 | WO |
9949910 | Oct 1999 | WO |
9951162 | Oct 1999 | WO |
9953863 | Oct 1999 | WO |
WO 9955406 | Nov 1999 | WO |
9960941 | Dec 1999 | WO |
9962430 | Dec 1999 | WO |
0009195 | Feb 2000 | WO |
WO 0015275 | Feb 2000 | WO |
0010623 | Mar 2000 | WO |
0012029 | Mar 2000 | WO |
WO 0013722 | Mar 2000 | WO |
0015146 | Mar 2000 | WO |
0015147 | Mar 2000 | WO |
WO 0015148 | Mar 2000 | WO |
0015148 | Mar 2000 | WO |
0015149 | Mar 2000 | WO |
0015275 | Mar 2000 | WO |
WO 0018302 | Apr 2000 | WO |
WO 0018323 | Apr 2000 | WO |
WO 0018325 | Apr 2000 | WO |
WO 0018326 | Apr 2000 | WO |
WO 0018331 | Apr 2000 | WO |
WO 0018462 | Apr 2000 | WO |
0021436 | Apr 2000 | WO |
0021461 | Apr 2000 | WO |
0021463 | Apr 2000 | WO |
0024449 | May 2000 | WO |
0028924 | May 2000 | WO |
0033725 | Jun 2000 | WO |
WO 0035376 | Jun 2000 | WO |
WO 0036997 | Jun 2000 | WO |
0041632 | Jul 2000 | WO |
0041633 | Jul 2000 | WO |
WO 0043051 | Jul 2000 | WO |
0045711 | Aug 2000 | WO |
WO 0045886 | Aug 2000 | WO |
0047139 | Aug 2000 | WO |
WO 0049952 | Aug 2000 | WO |
WO 0049954 | Aug 2000 | WO |
WO 0049956 | Aug 2000 | WO |
WO 0054660 | Sep 2000 | WO |
WO 0054661 | Sep 2000 | WO |
WO 0056224 | Sep 2000 | WO |
WO 0056225 | Sep 2000 | WO |
0056387 | Sep 2000 | WO |
0060995 | Oct 2000 | WO |
0066007 | Nov 2000 | WO |
0066009 | Nov 2000 | WO |
0066035 | Nov 2000 | WO |
WO 0069345 | Nov 2000 | WO |
WO 0069504 | Nov 2000 | WO |
0071195 | Nov 2000 | WO |
WO 0108566 | Feb 2001 | WO |
WO 0108602 | Feb 2001 | WO |
WO 0110340 | Feb 2001 | WO |
WO 0110341 | Feb 2001 | WO |
WO 0110347 | Feb 2001 | WO |
WO 0110348 | Feb 2001 | WO |
WO 0110349 | Feb 2001 | WO |
WO 0110350 | Feb 2001 | WO |
0117440 | Mar 2001 | WO |
1 097 676 | May 2001 | WO |
0149187 | Jul 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20020007138 A1 | Jan 2002 | US |
Number | Date | Country | |
---|---|---|---|
60099719 | Sep 1998 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09369061 | Aug 1999 | US |
Child | 09828794 | US |